Study identifier:NIS-CCH-DUM-2008/1
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Management of Diabetes Mellitus Patients with retinopathy
retinopathy
-
No
-
All
2500
Observational
N/A
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
Aim of this NIS is to retrospectively document the management of diabetic patients with retinopathy in a naturalistic setting in Switzerland. Following elements are going to be analyzed: - which medication are used to keep blood pressure under control? - which medication are used for metabolic control? - the average control level of metabolism and blood pressure is compliant with the international guidelines? - laser photocoagulation plays a role in the control of metabolism and blood pressure? - there are differences in the control of metabolism and blood pressure between patients with DM I or DM II? - there is an influence of renal failure on the choose of medication?
Location
Location
Aigle, VD, Switzerland
Location
Alle, JU, Switzerland
Location
Ardon, VS, Switzerland
Location
Ascona, TI, Switzerland
Location
Basel, BS, Switzerland
Location
Bassersdorf, ZH, Switzerland
Location
Bassins, VD, Switzerland
Location
Bern, BE, Switzerland
Arms | Assigned Interventions |
---|---|
1 Diabetic patients with retinopathy | - |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.